Mobile App

Google Play Apple Store
IPF Podcast: Rethinking the Patient Experience
AMA/ABS/ANCC/ACPE - Podcast
Idiopathic pulmonary fibrosis (IPF) presents ongoing challenges across the patient journey, from timely diagnosis to long-term disease management. Nonspecific symptoms often delays appropriate imaging and referral, while issues related to antifibrotic tolerability and treatment discontinuation may further complicate care. Clinicians must also consider changes in physiologic measures, including DLco, alongside emerging understanding of pulmonary vascular involvement and evolving therapeutic approaches.

In this podcast, Dr. Kevin Flaherty shares expert perspectives and case-based insights on recognizing IPF earlier, optimizing antifibrotic therapy, proactively addressing adverse events, and interpreting key diagnostic and prognostic indicators. Listen in to explore strategies that can help inform timely diagnosis, individualized treatment decisions, and ongoing care for patients living with IPF.
Click 'Continue to Activity' to begin and claim up to 0.75 AMA, ABS, ANCC, or ACPE credit/contact hour(s) after completion.
Kevin Flaherty, MD

Kevin Flaherty, MD

Director, Interstitial Lung Disease Program
University of Michigan Health

You Might be Interested in...

IPF Podcast: Rethinking the Patient Experience
AMA/ABS/ANCC/ACPE - Podcast

Kevin Flaherty, MD

Kevin Flaherty, MD

Director, Interstitial Lung Disease Program
University of Michigan Health

Idiopathic pulmonary fibrosis (IPF) presents ongoing challenges across the patient journey, from timely diagnosis to long-term disease management. Nonspecific symptoms often delays appropriate imaging and referral, while issues related to antifibrotic tolerability and treatment discontinuation may further complicate care. Clinicians must also consider changes in physiologic measures, including DLco, alongside emerging understanding of pulmonary vascular involvement and evolving therapeutic approaches.

In this podcast, Dr. Kevin Flaherty shares expert perspectives and case-based insights on recognizing IPF earlier, optimizing antifibrotic therapy, proactively addressing adverse events, and interpreting key diagnostic and prognostic indicators. Listen in to explore strategies that can help inform timely diagnosis, individualized treatment decisions, and ongoing care for patients living with IPF.
Click 'Continue to Activity' to begin and claim up to 0.75 AMA, ABS, ANCC, or ACPE credit/contact hour(s) after completion.
Kevin Flaherty, MD

Kevin Flaherty, MD

Director, Interstitial Lung Disease Program
University of Michigan Health


You Might be Interested in...


 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.


Overview

Idiopathic pulmonary fibrosis (IPF) presents ongoing challenges across the patient journey, from timely diagnosis to long-term disease management. Nonspecific symptoms often delays appropriate imaging and referral, while issues related to antifibrotic tolerability and treatment discontinuation may further complicate care. Clinicians must also consider changes in physiologic measures, including DLco, alongside emerging understanding of pulmonary vascular involvement and evolving therapeutic approaches.

In this podcast, Dr. Kevin Flaherty shares expert perspectives and case-based insights on recognizing IPF earlier, optimizing antifibrotic therapy, proactively addressing adverse events, and interpreting key diagnostic and prognostic indicators. Listen in to explore strategies that can help inform timely diagnosis, individualized treatment decisions, and ongoing care for patients living with IPF.

IPF Podcast: Rethinking the Patient Experience

AMA/ABS/ANCC/ACPE - Podcast
1 episode | 47 minutes

Kevin Flaherty, MD

Kevin Flaherty, MD

Director, Interstitial Lung Disease Program
University of Michigan Health

You Might be Interested in...


20
Supported by an independent educational grant from
United Therapeutics, a public benefit company.


Approved Educational Partner

Launch/Release Date: September 14, 2026
Activity Expiration Date: August 31, 2027

Multipage
8136
DtoD Podcast (700 x 250 px) (003).png
False
  • Pulmonology
Pulmonology
Change Settings